[1] SIACHISUMO C, LUZZI S, ALDALAQAN S, et al. An anciently diverged family of RNA binding proteins maintain correct splicing of a class of ultra-long exons through cryptic splice site repression[J]. eLife, 2024, 12: RP89705. [2] WANG Y P, ZHAO Z Y, GUO T T, et al. SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis[J]. NPJ Precis Oncol, 2024, 8(1): 58. [3] ZHANG Y J, LI L, YE Z H, et al. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma [J]. Ann Transl Med, 2021, 9(20): 1554. [4] ZHANG Z H, ZHANG C Q, YANG Z Y, et al. M(6)a regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer[J]. J Hematol Oncol, 2021, 14(1): 190. [5] YAN Q X, ZENG P, ZHOU X Q, et al. RBMX suppresses tumorigenicity and progression of bladder cancer by interacting with the hnRNP A1 protein to regulate PKM alternative splicing [J]. Oncogene, 2021, 40(15): 2635-2650. [6] PACHUAU L, LALREMMAWIA H, RALTE L, et al. Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe [J]. Breast Cancer Res Treat, 2025, 209(2): 375-387. [7] LIU Y, NIE J Y, HUANG Y, et al. m6A-related genes ALKBH5 and RBMX as prognostic and progression biomarkers in Chinese oral squamous cell carcinoma patients[J]. Arch Oral Biol, 2025, 170: 106149. [8] WU H Y, DONG H L, FU Y, et al. Expressions of m6A RNA methylation regulators and their clinical predictive value in cervical squamous cell carcinoma and endometrial adenocarcinoma[J]. Clin Exp Pharmacol Physiol, 2021, 48(2): 270-278. [9] SHOJI Y, KOYANAGI K, KANAMORI K, et al. Immunotherapy for esophageal cancer: Where are we now and where can we go[J]. World J Gastroenterol, 2024, 30(19): 2496-2501. [10] DEBOEVER N, JONES C M, YAMASHITA K, et al. Advances in diagnosis and management of cancer of the esophagus[J]. BMJ, 2024, 385: e074962. [11] EISNER D C. Esophageal cancer: Treatment advances and need for screening[J]. JAAPA, 2024, 37(4): 19-24. [12] SHENG Y L, LEI K J, SUN C P, et al. Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response[J]. Aging, 2024, 16(1): 226-245. [13] CHI C, HOU W J, ZHANG Y, et al. PDHB-AS suppresses cervical cancer progression and cisplatin resistance via inhibition on Wnt/β-catenin pathway[J]. Cell Death Dis, 2023, 14(2): 90. [14] SONG Y N, HE S F, MA X, et al. RBMX contributes to hepatocellular carcinoma progression and sorafenib resistance by specifically binding and stabilizing BLACAT1[J]. Am J Cancer Res, 2020, 10(11): 3644-3665. [15] KIRI S, RYBA T. Cancer, metastasis, and the epigenome[J]. Mol Cancer, 2024, 23(1): 154. [16] TOMECKA P, KUNACHOWICZ D, GÓRCZYŃSKA J, et al. Factors determining epithelial-mesenchymal transition in cancer progression[J]. Int J Mol Sci, 2024, 25(16): 8972. [17] DAKAL T C, BHUSHAN R, XU C M, et al. Intricate relationship between cancer stemness, metastasis, and drug resistance[J]. MedComm, 2024, 5(10): e710. |